

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal (STA)

Ixezumab for treating moderate to severe plaque psoriasis [ID904]

## Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Eli Lilly (ixekizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Against Allergy</li> <li>• Allergy UK</li> <li>• Black Health Agency</li> <li>• Changing Faces</li> <li>• Muslim Council of Britain</li> <li>• Psoriasis Association</li> <li>• Psoriasis and Psoriatic Arthritis Alliance</li> <li>• Psoriasis Help Organisation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Skin Foundation</li> <li>• British Society for Cutaneous Allergy</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS South Worcestershire CCG</li> <li>• NHS Tower Hamlets CCG</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AbbVie Limited (adalimumab)</li> <li>• Accord Healthcare (methotrexate)</li> <li>• Allergan (acitretin)</li> <li>• B&amp;S Colorama Pharmaceuticals (ciclosporin)</li> <li>• Cubic Pharmaceuticals (ciclosporin)</li> <li>• Dexcel Pharma (ciclosporin)</li> <li>• Genus Pharmaceuticals (acitretin)</li> <li>• Hameln Pharmaceuticals (methotrexate)</li> <li>• Hospira (infliximab, methotrexate)</li> <li>• Janssen (ustekinumab)</li> <li>• Medac Ltd (methotrexate)</li> <li>• Merck Sharp &amp; Dohme (infliximab)</li> <li>• Mylan UK (ciclosporin)</li> <li>• Napp (infliximab)</li> <li>• Novartis Pharmaceuticals</li> </ul>

National Institute for Health and Care Excellence  
 Final matrix for the single technology appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Welsh Government</li> </ul>	<p>(secukinumab, ciclosporin)</p> <ul style="list-style-type: none"> <li>• Orion Pharma UK (methotrexate)</li> <li>• Pfizer (etanercept, methotrexate)</li> <li>• Sandoz (methotrexate)</li> <li>• Teva UK (methotrexate)</li> <li>• Wockhardt UK (methotrexate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Epidermo-Epidemiology Society</li> <li>• Centre of Evidence-based Dermatology, University of Nottingham</li> <li>• Cochrane Skin Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.